Culturing and Expansion of “Clinical Grade” Neural Stem Cells from the Fetal Human Central Nervous System

Maurizio Gelati, Daniela Celeste Profico, Daniela Ferrari, Angelo Luigi Vescovi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

NSCs have been demonstrated to be very useful in grafts into the mammalian central nervous system to investigate the exploitation of NSC for the therapy of neurodegenerative disorders in animal models of neurodegenerative diseases. To push cell therapy in CNS on stage of clinical application, it is necessary to establish a continuous and standardized, clinical grade (i.e., produced following the good manufacturing practice guidelines) human neural stem cell lines. In this chapter we will illustrate some of the protocols for the production and characterization routinely used into our GMP “cell factory” for the production of “clinical grade” human neural stem cell lines already in use in clinical trials on neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS— Clinicaltrials.gov number NCT01640067) and secondary progressive multiple sclerosis (SPMS— Clinicaltrials.gov number NCT03282760).

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press
Pages57-66
Number of pages10
DOIs
StatePublished - 2022

Publication series

NameMethods in Molecular Biology
Volume2389
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029

Keywords

  • Clinical grade
  • Human central nervous system
  • Neural stem cells
  • Precursor cells
  • Therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Fingerprint

Dive into the research topics of 'Culturing and Expansion of “Clinical Grade” Neural Stem Cells from the Fetal Human Central Nervous System'. Together they form a unique fingerprint.

Cite this